haloperidol and Shock

haloperidol has been researched along with Shock in 3 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.

Research

Studies (3)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Average Duration of Study Infusion

average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Average Maximum Rate of Study Infusion

average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Intensive Care Unit Length of Stay

length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit

Number of Delirium-free Days

Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization

Number of Mechanical Ventilator Free Days

number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization

Number of Participants With Delirium Resolution

defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization

Occurrence of Agitation Requiring Use of Rescue Sedatives While on Study Infusion

number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Delirium Duration

Duration of delirium during the intervention period (NCT01211522)
Timeframe: 14 days

Delirium/Coma-free Days (DCFDs)

Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma. (NCT01211522)
Timeframe: 14 days

Number of Participants With Extrapyramidal Symptoms

(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)

Number of Participants With Neuroleptic Malignant Syndrome

(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)

Number of Participants With Torsades de Pointes

(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)

Time to Final ICU Discharge

"Days from randomization to final, successful ICU discharge, where successful indicates that discharge was followed by at least 48 hours alive. ICU discharge is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU." (NCT01211522)
Timeframe: 90 days

Time to Hospital Discharge

"Days from randomization to successful hospital discharge, where successful indicates that discharge was followed by at least 48 hours alive." (NCT01211522)
Timeframe: 90 days

Time to ICU Readmission

Days from first ICU discharge to next ICU readmission. (NCT01211522)
Timeframe: 90 days after first ICU discharge

Time to Liberation From Mechanical Ventilation

"Days from randomization to successful liberation from mechanical ventilation, where successful indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation." (NCT01211522)
Timeframe: 30 days

Mortality

Deaths within the specified timeframe (NCT01211522)
Timeframe: 30-day and 90-day

Trials

1 trial available for haloperidol and Shock

Other Studies

2 other studies available for haloperidol and Shock